Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 16/20 | 0.64 |
| ▸ | NPY1R | P25929 | 11/20 | 0.64 |
| ▸ | NPY5R | Q15761 | 9/20 | 0.64 |
| ▸ | NPY2R | P49146 | 7/20 | 0.64 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8588358 | 0.91 | NPY4R (0.57) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL8588362 | 0.91 | NPY4R (0.57) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL30395514 | 0.91 | NPY4R (0.70) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL29941335 | 0.91 | NPY4R (0.71) | NPY4RNPY1RNPY5RNPY2ROPRK1 | |
| SCHEMBL29940984 | 0.91 | NPY4R (0.71) | NPY4RNPY1RNPY5RNPY2ROPRK1 | |
| SCHEMBL29370105 | 0.91 | NPY4R (0.55) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL31257949 | 0.90 | NPY4R (0.67) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL30008086 | 0.90 | NPY4R (0.59) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL30008293 | 0.89 | NPY4R (0.60) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL31182633 | 0.89 | NPY4R (0.60) | NPY4RNPY1RNPY5RNPY2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1986694-B1 | COUPLING OF POLYPEPTIDES AT THE C-TERMINUS | NOVO NORDISK HEALTHCARE AG (CH) | 2015-06-10 | — | — | EP | disclosed |
| US-20140045753-A1 | COUPLING OF POLYPEPTIDES AT THE C-TERMINUS | NOVO NORDISK HEALTH CARE AG (CH) | 2014-02-13 | — | — | US | disclosed |
| US-20090082254-A1 | Coupling of Polypeptides at the C-Terminus | NOVO NORDISK A/S (DK) | 2009-03-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082254-A1 | Coupling of Polypeptides at the C-Terminus | PTMS, VIP, LNPEP | NPY4R 1896/4885NPY1R 1877/4885NPY5R 1830/4885 |
| US-20140045753-A1 | COUPLING OF POLYPEPTIDES AT THE C-TERMINUS | PTMS, VIP, LNPEP | NPY4R 1896/4885NPY1R 1877/4885NPY5R 1830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.